1. ISS recommends Neuphoria shareholders vote for management's nominees. 2. Board actions recognized as appropriate in response to clinical trial outcomes. 3. Lynx1's opposition lacks a compelling case for change. 4. Strategic alternatives process aims to maximize shareholder value. 5. Neuphoria emphasizes transparency and proactive governance.
FAQ
Why Bullish?
The ISS recommendation typically supports stock stability and confidence, positively influencing NEUP.
How important is it?
The article addresses a managerial vote with potential direct effects on NEUP's stock value.
Why Short Term?
The upcoming vote will directly impact governance and stock performance in the near term.
Neuphoria Therapeutics (NASDAQ: NEUP) Receives ISS Recommendation for Director Nominees
BURLINGTON, Mass., December 08, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (NASDAQ: NEUP), a biotechnology company focused on developing therapies for neuropsychiatric disorders, has garnered a significant endorsement from Institutional Shareholders Services (ISS). The independent proxy advisory firm has advised Neuphoria shareholders to vote on the WHITE proxy card in favor of both director nominees proposed by the company, Peter Miles Davies and David Wilson.
Context of the Proxy Contest
The recommendation comes amid a proxy contest initiated by Lynx1 Capital Management, which is advocating for the election of two alternate director candidates at Neuphoria's 2025 Annual Meeting. However, the current Neuphoria Board of Directors has unanimously recommended Davies and Wilson, emphasizing their robust qualifications and strategic vision for the company's future.
Neuphoria's Response to ISS Recommendation
In response to ISS's recommendation, Neuphoria issued a statement expressing satisfaction with the detailed evaluation performed by ISS. The company noted:
- Timely Actions: The Board has acted proactively regarding its Phase 3 clinical trial data and ongoing capital raises.
- Commitment to Shareholders: The recommendation indicates ISS's approval of the Board's efforts to maximize shareholder value.
- Strategic Alternatives Process: Neuphoria believes this process must be allowed to reach its full potential to benefit shareholders.
ISS's Findings
In its report dated December 4, 2025, ISS praised the Board for its actions in response to a previous clinical trial setback and its management of the dissident's offer. Specifically, ISS stated:
“The board's actions to date, both in response to the clinical trial failure and to the dissident's latest offer, appear appropriate.”
“The board has committed to transparency in the process, and it has provided recent updates to shareholders.”
ISS concluded that the dissident's case for change was unconvincing, reinforcing their recommendation to support Neuphoria’s management nominees on the WHITE proxy card.
Call to Action for Shareholders
Neuphoria strongly urges all shareholders to follow the ISS's guidance by voting “FOR” both Peter Miles Davies and David Wilson and “WITHHOLD” votes for Lynx1's nominees on the WHITE proxy card. Shareholders who have questions or require assistance with the voting process can reach out to Sodali & Co at (203) 658-9400 or via email at NEUP@investor.sodali.com.
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is committed to developing innovative therapies for individuals facing neuropsychiatric challenges. The company’s lead candidate, BNC210, aims to treat post-traumatic stress disorder (PTSD) and is distinguished as a first-of-its-kind treatment with a focus on restoring neurotransmitter balance.
Following the AFFIRM-1 Phase 3 clinical trial results announced on October 20, 2025, Neuphoria is conducting a strategic review as it seeks to navigate its future developments, including partnerships and early-stage clinical trials targeting Alzheimer’s disease treatment options.
Forward-Looking Statements
Forward-looking statements contained in this release are based on current expectations and beliefs. These include projections related to Neuphoria's business expansion, successful product development outcomes, market potential for its therapies, and financial strategies. Actual results may vary due to various risk factors inherent to the biotechnology sector and other uncertainties detailed in the company's filings with the SEC.